These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19890692)

  • 1. Docetaxel: its role in current and future treatments for advanced gastric cancer.
    Nishiyama M; Wada S
    Gastric Cancer; 2009; 12(3):132-41. PubMed ID: 19890692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Progress in chemotherapy for advanced gastric cancer].
    Xu RH; Teng KY
    Ai Zheng; 2009 Oct; 28(10):1108-13. PubMed ID: 19799823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastric cancer. Treatment of advanced disease and new drugs.
    Caponigro F; Facchini G; Nasti G; Iaffaioli RV
    Front Biosci; 2005 Sep; 10():3122-6. PubMed ID: 15970566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for advanced gastric cancer.
    Wagner AD; Unverzagt S; Grothe W; Kleber G; Grothey A; Haerting J; Fleig WE
    Cochrane Database Syst Rev; 2010 Mar; (3):CD004064. PubMed ID: 20238327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel in the treatment of gastric cancer.
    Thuss-Patience PC; Kretzschmar A; Reichardt P
    Future Oncol; 2006 Oct; 2(5):603-20. PubMed ID: 17026452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen.
    Ajani JA
    Cancer; 2008 Sep; 113(5):945-55. PubMed ID: 18623382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel.
    Ajani JA
    Expert Opin Pharmacother; 2006 Aug; 7(12):1627-31. PubMed ID: 16872265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey.
    Teker F; Yilmaz B; Kemal Y; Kut E; Yucel I
    Asian Pac J Cancer Prev; 2014; 15(16):6727-32. PubMed ID: 25169516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
    Pozzo C; Barone C
    Oncologist; 2008 Jul; 13(7):794-806. PubMed ID: 18614586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel in advanced gastric cancer--review of the main clinical trials.
    Di Cosimo S; Ferretti G; Fazio N; Silvestris N; Carlini P; Alimonti A; Gelibter A; Felici A; Papaldo P; Cognetti F
    Acta Oncol; 2003; 42(7):693-700. PubMed ID: 14690154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
    J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study.
    Maeda O; Matsuoka A; Miyahara R; Funasaka K; Hirooka Y; Fukaya M; Nagino M; Kodera Y; Goto H; Ando Y
    World J Gastroenterol; 2017 Feb; 23(6):1090-1097. PubMed ID: 28246483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Isikdogan A
    Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in study on the treatment of gastric cancer with docetaxel].
    Zhang G; Du H; Wang Z; Ren Y; Wang K; Jiao Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Feb; 43(2):216-221. PubMed ID: 29559609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of advanced gastric cancer.
    Rivera F; Vega-Villegas ME; López-Brea MF
    Cancer Treat Rev; 2007 Jun; 33(4):315-24. PubMed ID: 17376598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
    Mody MD; Gill HS; Saba NF
    JAMA Otolaryngol Head Neck Surg; 2016 Sep; 142(9):898-905. PubMed ID: 27389786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
    Kim YJ; Goh PG; Kim ES; Lee SY; Moon HS; Lee ES; Sung JK; Kim SH; Lee BS; Jeong HY
    Korean J Gastroenterol; 2011 Dec; 58(6):311-7. PubMed ID: 22198228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel in advanced gastric cancer.
    Haller DG; Misset JL
    Anticancer Drugs; 2002 Jun; 13(5):451-60. PubMed ID: 12045456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.